PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer

• Autores: J. Li, Z. Yang, Q. Zou, Y. Yuan, J. Li, L. Liang, G. Zeng, S. Chen
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 16, Nº. 2, 2014, págs. 200-207
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To identify biological markers related to the progression and prognosis of GBC.

    Methods The expressions of pyruvate kinase isoenzyme type M2 (PKM2) and activin A receptor type IC (ACVR 1C) in 46 squamous cell/adenosquamous carcinomas (SC/ASC) and 80 adenocarcinomas (AC) were examined using immunohistochemistry.

    Results Positive PKM2 and negative ACVR 1C expressions were significantly associated with lymph node metastasis, invasion and TNM stage of SC/ASCs and ACs. Univariate Kaplan�Meier analysis showed that either elevated PKM2 or loss of ACVR 1C expression significantly correlated with shorter average survival times in both SC/ASC and AC patients. Multivariate Cox regression analysis showed that positive PKM2 expression and loss of ACVR 1C expression were poor prognosis biomarkers in both SC/ASC and AC patients.

    Conclusions Our study suggested that PKM2 overexpression is a marker of metastasis, invasion and poor prognosis of GBC. ACVR 1C is a tumor suppressor, and lowered ACVR 1C expression is an important marker for the metastasis, invasion, and prognosis of GBC.